SG157422A1 - Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent - Google Patents
Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agentInfo
- Publication number
- SG157422A1 SG157422A1 SG200907918-7A SG2009079187A SG157422A1 SG 157422 A1 SG157422 A1 SG 157422A1 SG 2009079187 A SG2009079187 A SG 2009079187A SG 157422 A1 SG157422 A1 SG 157422A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- chemotherapeutic agent
- oligomer
- proliferative diseases
- antisense iap
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51626303P | 2003-10-30 | 2003-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG157422A1 true SG157422A1 (en) | 2009-12-29 |
Family
ID=34549513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200907918-7A SG157422A1 (en) | 2003-10-30 | 2004-10-29 | Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent |
Country Status (17)
Country | Link |
---|---|
US (1) | US8012944B2 (es) |
EP (1) | EP1691842A4 (es) |
JP (1) | JP2007509861A (es) |
KR (1) | KR20060127393A (es) |
CN (2) | CN1901939A (es) |
AU (1) | AU2004284855A1 (es) |
BR (1) | BRPI0415779A (es) |
CA (1) | CA2542884A1 (es) |
IL (1) | IL175242A0 (es) |
MX (1) | MXPA06004920A (es) |
NO (1) | NO20062420L (es) |
NZ (1) | NZ547191A (es) |
RU (2) | RU2376018C2 (es) |
SG (1) | SG157422A1 (es) |
TW (1) | TWI332841B (es) |
WO (1) | WO2005042030A1 (es) |
ZA (1) | ZA200603399B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
ATE431410T1 (de) | 2002-03-27 | 2009-05-15 | Aegera Therapeutics Inc | Gegen iap gerichtete antisense-nukleobasen und deren verwendungen |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
US20080293653A1 (en) * | 2004-10-14 | 2008-11-27 | Jon Durkin | Method of treating autoimmune diseases |
AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
CN101437943A (zh) * | 2006-05-03 | 2009-05-20 | 波罗的科技发展有限公司 | 牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂 |
US20080293053A1 (en) * | 2006-12-28 | 2008-11-27 | The Regents Of The University Of Michigan | shRNA Materials and Methods of Using Same for Inhibition of DKK-1 |
US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
US9095568B2 (en) * | 2007-09-26 | 2015-08-04 | Mark Berninger | Therapeutic and vaccine polyelectrolyte nanoparticle compositions |
US8288520B2 (en) * | 2008-10-27 | 2012-10-16 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and system |
JP6108661B2 (ja) * | 2009-01-28 | 2017-04-05 | キアジェン ゲイサーズバーグ インコーポレイテッド | 配列特異的な大量試料調製方法およびアッセイ法 |
CA2760542A1 (en) * | 2009-05-01 | 2010-11-04 | Qiagen Gaithersburg, Inc. | A non-target amplification method for detection of rna splice-forms in a sample |
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
BR112012018545A2 (pt) | 2010-01-29 | 2016-05-03 | Qiagen Gaithersburg Inc | método de determinação e confirmação da presença de um hpv em uma amostra |
WO2011094514A1 (en) * | 2010-01-29 | 2011-08-04 | Qiagen Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
US9506057B2 (en) | 2010-03-26 | 2016-11-29 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
JP2013528049A (ja) | 2010-05-19 | 2013-07-08 | キアゲン ガイサーズバーグ アイエヌシー. | 核酸の配列特異的な精製及び多重分析のための方法及び組成物 |
US9376727B2 (en) | 2010-05-25 | 2016-06-28 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically truncated probes |
JP6053684B2 (ja) * | 2010-09-07 | 2016-12-27 | インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド | アンチセンス化合物の修飾 |
CA2828224A1 (en) | 2011-02-24 | 2012-08-30 | Qiagen Gaithersburg, Inc. | Materials and methods for detection of hpv nucleic acids |
CN102731591B (zh) * | 2011-03-30 | 2016-12-14 | 江苏中康药物科技有限公司 | 一种抗肿瘤、抗病毒的化合物、其制备方法及用途 |
KR20140084232A (ko) | 2011-10-25 | 2014-07-04 | 아이시스 파마수티컬즈 인코포레이티드 | Gccr 발현의 안티센스 조절 |
US9644207B2 (en) * | 2013-03-14 | 2017-05-09 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Tau expression |
SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
WO2017214553A1 (en) * | 2016-06-09 | 2017-12-14 | The General Hospital Corporation | Modulating the cellular stress response |
RU2664182C2 (ru) * | 2016-12-05 | 2018-08-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" | Способ получения препарата для регуляции численности комара обыкновенного (Culex pipiens) |
CN108794569A (zh) * | 2018-06-27 | 2018-11-13 | 南开大学 | 天然产物Symplostatin4衍生物及其在制备抗癌症干细胞药物中的应用 |
US20230029259A1 (en) * | 2019-12-02 | 2023-01-26 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents |
US20230066380A1 (en) * | 2020-01-23 | 2023-03-02 | University Of Southern California | Antagonism as a therapy for tdp-43 proteinopathies |
CN110982876B (zh) * | 2020-03-04 | 2020-05-26 | 圣湘生物科技股份有限公司 | 病毒核酸检测的预处理方法、预处理液、试剂盒及其用途 |
CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665550A (en) | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5594076A (en) | 1991-09-24 | 1997-01-14 | The Pennsylvania Research Foundation | Hydrodegradable polyesters |
US6265157B1 (en) | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
US20030073159A1 (en) | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
WO1994006814A1 (en) | 1992-09-14 | 1994-03-31 | The General Hospital Corporation | Ikaros: a t cell pathway regulatory gene |
US5958771A (en) | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US5958772A (en) | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
US6087173A (en) | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
WO1994023760A1 (en) | 1993-04-14 | 1994-10-27 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5691179A (en) | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5510239A (en) | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
AU704601B2 (en) | 1994-01-18 | 1999-04-29 | Scripps Research Institute, The | Zinc finger protein derivatives and methods therefor |
WO1995028497A1 (en) | 1994-04-13 | 1995-10-26 | La Jolla Cancer Research Foundation | Interaction of proteins involved in a cell death pathway |
SI9520059A (en) | 1994-05-10 | 1997-08-31 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis. |
ATE314469T1 (de) | 1994-10-18 | 2006-01-15 | Univ Ottawa | Neuronales apotose-inhibitor protein, gen sequenz und mutationen die wirbelsäulenmuskelatrophie verursachen |
EP0787147A1 (en) | 1994-10-25 | 1997-08-06 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
AU4695296A (en) | 1995-01-06 | 1996-07-24 | Immulogic Pharmaceutical Corporation | Compositions and methods for treating rheumatoid arthritis |
CA2220670A1 (en) | 1995-05-11 | 1996-11-14 | Peter L. Hudson | Human inhibitor of apoptosis gene 1 |
US5770690A (en) | 1995-06-27 | 1998-06-23 | Neurex Corporation | Bax omega protein and methods |
US5877021A (en) | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US5919912A (en) | 1995-08-04 | 1999-07-06 | University Of Ottawa | Mammalian IAP antibodies and diagnostic kits |
AU6692996A (en) | 1995-08-08 | 1997-03-05 | Tularik Inc. | Inhibitors of apoptosis |
US6187557B1 (en) | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
US5834216A (en) | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
AUPN727595A0 (en) | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
US5605022A (en) | 1995-12-26 | 1997-02-25 | Nci Building Systems, Inc. | Vented closure |
GB9601108D0 (en) | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US6133437A (en) | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
AU5065098A (en) | 1996-11-15 | 1998-06-10 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6228603B1 (en) | 1997-05-22 | 2001-05-08 | The Burnham Institute | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
CA2225187A1 (en) | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
CA2306423A1 (en) | 1997-10-14 | 1999-04-22 | Nadine A. Tatton | Methods for increasing schwann cell survival |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6171821B1 (en) | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
EP1117391A2 (en) | 1998-10-09 | 2001-07-25 | L. Sai Latha Shankar | Methods for treating multiple sclerosis |
US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
KR20000065690A (ko) | 1999-04-08 | 2000-11-15 | 박종구 | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 dna 및 그 제조방법 |
US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20020119168A1 (en) * | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
KR100397275B1 (ko) | 2001-03-08 | 2003-09-17 | 주식회사 웰진 | 단방향성 안티센스 cDNA 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템 |
WO2003076592A2 (en) | 2002-03-06 | 2003-09-18 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of sirna molecules |
ATE431410T1 (de) | 2002-03-27 | 2009-05-15 | Aegera Therapeutics Inc | Gegen iap gerichtete antisense-nukleobasen und deren verwendungen |
EP1469070A1 (en) | 2003-04-15 | 2004-10-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Livin-specific siRNAs for the treatment of therapy-resistant tumors |
AU2004275903B2 (en) | 2003-09-29 | 2012-04-12 | Topigen Pharmaceutique Inc. | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
-
2004
- 2004-10-28 US US10/975,790 patent/US8012944B2/en not_active Expired - Fee Related
- 2004-10-29 CN CNA2004800396018A patent/CN1901939A/zh active Pending
- 2004-10-29 KR KR1020067010619A patent/KR20060127393A/ko active IP Right Grant
- 2004-10-29 EP EP04789807A patent/EP1691842A4/en not_active Withdrawn
- 2004-10-29 ZA ZA200603399A patent/ZA200603399B/en unknown
- 2004-10-29 RU RU2006117024/15A patent/RU2376018C2/ru not_active IP Right Cessation
- 2004-10-29 TW TW093132984A patent/TWI332841B/zh not_active IP Right Cessation
- 2004-10-29 NZ NZ547191A patent/NZ547191A/xx unknown
- 2004-10-29 AU AU2004284855A patent/AU2004284855A1/en not_active Abandoned
- 2004-10-29 BR BRPI0415779-6A patent/BRPI0415779A/pt not_active IP Right Cessation
- 2004-10-29 CA CA002542884A patent/CA2542884A1/en not_active Abandoned
- 2004-10-29 WO PCT/CA2004/001900 patent/WO2005042030A1/en active Application Filing
- 2004-10-29 SG SG200907918-7A patent/SG157422A1/en unknown
- 2004-10-29 JP JP2006537023A patent/JP2007509861A/ja active Pending
- 2004-10-29 MX MXPA06004920A patent/MXPA06004920A/es active IP Right Grant
- 2004-10-29 CN CN201010218334A patent/CN101862459A/zh active Pending
-
2006
- 2006-04-26 IL IL175242A patent/IL175242A0/en unknown
- 2006-05-29 NO NO20062420A patent/NO20062420L/no not_active Application Discontinuation
-
2010
- 2010-01-15 RU RU2010101234/15A patent/RU2010101234A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200528117A (en) | 2005-09-01 |
CN101862459A (zh) | 2010-10-20 |
JP2007509861A (ja) | 2007-04-19 |
IL175242A0 (en) | 2006-09-05 |
RU2010101234A (ru) | 2011-07-20 |
US8012944B2 (en) | 2011-09-06 |
CN1901939A (zh) | 2007-01-24 |
CA2542884A1 (en) | 2005-05-12 |
AU2004284855A1 (en) | 2005-05-12 |
BRPI0415779A (pt) | 2006-12-26 |
ZA200603399B (en) | 2007-09-26 |
WO2005042030A1 (en) | 2005-05-12 |
RU2376018C2 (ru) | 2009-12-20 |
US20050119217A1 (en) | 2005-06-02 |
EP1691842A1 (en) | 2006-08-23 |
KR20060127393A (ko) | 2006-12-12 |
NO20062420L (no) | 2006-07-31 |
RU2006117024A (ru) | 2007-12-10 |
NZ547191A (en) | 2009-08-28 |
TWI332841B (en) | 2010-11-11 |
MXPA06004920A (es) | 2007-02-16 |
EP1691842A4 (en) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG157422A1 (en) | Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent | |
HK1093064A1 (en) | Thienopyrimidine derivatives as potassium channel inhibitors | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
SE0301700D0 (sv) | Novel compounds | |
MXPA05014166A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
RS20060320A (en) | Substituted indazole-o-glucosides | |
TW200510407A (en) | Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors | |
SG130189A1 (en) | Substituted indole-o-glucosides | |
WO2006020768A3 (en) | Chemically modified oligonucleotides | |
MXPA05002440A (es) | Composiciones y kits para la eliminacion de compuestos irritantes de superficies corporales. | |
EP1797281A4 (en) | METHOD OF ESTIMATING THE GEOMETRY OF A FRACTURE, COMPOSITIONS AND ARTICLES RELATED THERETO | |
UA87991C2 (en) | Substituted indole-o-glucosides | |
MXPA04006614A (es) | Deazapurinas y usos de las mismas. | |
PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
WO2004044160A3 (en) | Muc1 interference rna compositions and methods derived therefrom | |
IL187079A0 (en) | An oligoadenylate synthetase 1 protein, therapeutic compositions containing the same and screening methods | |
HUP0300848A2 (hu) | Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére | |
TW200510398A (en) | Novel compounds | |
AU2003297568A8 (en) | Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass | |
WO2006091965A3 (en) | Nod1 as an anti-tumor agent | |
TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
MXPA05012742A (es) | Composiciones de tratamiento para el cabello. | |
MXPA05008817A (es) | Derivados de esteres lipidos de nucleotidos. | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. |